Bleeding disorder, platelet-type, 13, susceptibility to

Summary

Bleeding disorder, platelet-type, 13, susceptibility to (MONDO:0800447) is a disease with 1 cohort gene.

At a glance

• Cohort genes: 1
• ClinVar variants: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bleeding disorder, platelet-type, 13, susceptibility to
Mondo ID	MONDO:0800447
OMIM	614009
UMLS	C3279614
MedGen	481244
Is cancer (heuristic)	no

Also known as: BDPLT13 · bleeding disorder, platelet-type, 13, susceptibility to · bleeding disorder, susceptibility to, due to defective platelet thromboxane A2 receptor · susceptibility to platelet-type bleeding disorder 13

Data availability: 14 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease susceptibility › inherited disease susceptibility › bleeding disorder, platelet-type, 13, susceptibility to

Related subtypes (283): microvascular complications of diabetes, susceptibility, Mycobacterium tuberculosis, susceptibility, bacteremia, susceptibility, pregnancy loss, recurrent, susceptibility, autoimmune thyroid disease, susceptibility to, susceptibility to HIV infection, appendicitis, proneness to, atherosclerosis susceptibility, multiple sclerosis, susceptibility to, dyslexia, susceptibility to, 1, endometriosis, susceptibility to, 1, osteoarthritis susceptibility 2, essential hypertension, genetic, osteoarthritis susceptibility 1, otitis media, susceptibility to, pelvic organ prolapse, susceptibility to, pulmonary edema of mountaineers, susceptibility to, sarcoidosis, susceptibility to, 1, strabismus, susceptibility to, thyrotoxic periodic paralysis, susceptibility to, 1, predisposition to invasive fungal disease due to CARD9 deficiency, celiac disease, susceptibility to, 1, hemolytic uremic syndrome, atypical, susceptibility to, 1, hypervitaminosis a, susceptibility to, kuru, susceptibility to, leprosy, susceptibility to, 3, nonarteritic anterior ischemic optic neuropathy, susceptibility to, diabetes mellitus, insulin-dependent, X-linked, susceptibility to, coronary heart disease, susceptibility to, 3, dyslexia, susceptibility to, 9, systemic lupus erythematosus, susceptibility to, 15, Leber optic atrophy, susceptibility to, dyslexia, susceptibility to, 2, Helicobacter pylori infection, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 1, inherited susceptibility to asthma, renal dysplasia, cystic, susceptibility to, systemic lupus erythematosus, susceptibility to, 1, leishmaniasis, tegumentary, susceptibility to, xanthomatosis, susceptibility to, hyperlipidemia, combined, 1, urinary tract infections, recurrent, susceptibility to, hypertension, essential, susceptibility to, 1, hepatic fibrosis, severe, susceptibility to, due to Schistosoma mansoni infection, dyslexia, susceptibility to, 3, Ascaris lumbricoides infection, susceptibility to, hypertension, essential, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 7, systemic lupus erythematosus, susceptibility to, 2, systemic lupus erythematosus, susceptibility to, 3, nephrolithiasis, uric acid, susceptibility to, atrioventricular septal defect, susceptibility to, 2, vitiligo-associated multiple autoimmune disease susceptibility 1, polysubstance abuse, susceptibility to, dyslexia, susceptibility to, 6, glaucoma, normal tension, susceptibility to, anorexia nervosa, susceptibility to, 1, stroke, susceptibility to, 1, dyslexia, susceptibility to, 5, epilepsy, idiopathic generalized, susceptibility to, 2, familial meningioma, celiac disease, susceptibility to, 5, systemic lupus erythematosus with hemolytic anemia, susceptibility to, 1, hypertension, essential, susceptibility to, 3, coronary heart disease, susceptibility to, 1, bulimia nervosa, susceptibility to, 1, leprosy, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 9, Parkinson disease 11, autosomal dominant, susceptibility to, focal segmental glomerulosclerosis 3, susceptibility to, autoimmune disease, susceptibility to, 1, osteoarthritis susceptibility 3, systemic lupus erythematosus with nephritis, susceptibility to, 1, systemic lupus erythematosus with nephritis, susceptibility to, 2, systemic lupus erythematosus with nephritis, susceptibility to, 3, coronary heart disease, susceptibility to, 2, coronary heart disease, susceptibility to, 4, autoimmune disease, susceptibility to, 2, autoimmune disease, susceptibility to, 3, systemic lupus erythematosus, susceptibility to, 4, myocardial infarction, susceptibility to, major depressive disorder 1, legionnaire disease, susceptibility to, myocardial infarction, susceptibility to, 2, major depressive disorder 2, hypertension, essential, susceptibility to, 4, epilepsy, idiopathic generalized, susceptibility to, 3, myoclonic epilepsy, juvenile, susceptibility to, 3, orofacial cleft 6, susceptibility to, coronary heart disease, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 1, attention deficit-hyperactivity disorder, susceptibility to, 2, attention deficit-hyperactivity disorder, susceptibility to, 3, attention deficit-hyperactivity disorder, susceptibility to, 4, Alzheimer disease 9, susceptibility to respiratory infections associated with CD8alpha chain mutation, dyslexia, susceptibility to, 8, autoimmune disease, susceptibility to, 4, hepatitis C virus, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 4, celiac disease, susceptibility to, 4, celiac disease, susceptibility to, 2, celiac disease, susceptibility to, 3, leprosy, susceptibility to, 1, systemic lupus erythematosus, susceptibility to, 5, systemic lupus erythematosus, susceptibility to, 6, opioid dependence, susceptibility to, 1, systemic lupus erythematosus, susceptibility to, 7, systemic lupus erythematosus, susceptibility to, 8, hypertension, essential, susceptibility to, 5, hypertension, essential, susceptibility to, 6, Parkinson disease 13, autosomal dominant, susceptibility to, West Nile virus, susceptibility to, hepatitis B virus, susceptibility to, Buruli ulcer, susceptibility to, osteoarthritis susceptibility 4, systemic lupus erythematosus, susceptibility to, 9, coronary heart disease, susceptibility to, 7, hypertension, essential, susceptibility to, 7, leprosy, susceptibility to, 4, hypertension, essential, susceptibility to, 8, epilepsy, idiopathic generalized, susceptibility to, 13, coronary heart disease, susceptibility to, 8, myoclonic epilepsy, juvenile, susceptibility to, 4, susceptibility to visceral leishmaniasis, 2, susceptibility to visceral leishmaniasis, 3, celiac disease, susceptibility to, 6, epilepsy, idiopathic generalized, susceptibility to, 5, epilepsy, childhood absence, susceptibility to, 6, celiac disease, susceptibility to, 7, celiac disease, susceptibility to, 8, celiac disease, susceptibility to, 9, celiac disease, susceptibility to, 10, celiac disease, susceptibility to, 11, celiac disease, susceptibility to, 12, celiac disease, susceptibility to, 13, coronary heart disease, susceptibility to, 9, systemic lupus erythematosus, susceptibility to, 10, systemic lupus erythematosus, susceptibility to, 11, systemic lupus erythematosus, susceptibility to, 12, epilepsy, childhood absence, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 6, systemic lupus erythematosus, susceptibility to, 13, sarcoidosis, susceptibility to, 2, sarcoidosis, susceptibility to, 3, osteoarthritis susceptibility 5, osteoarthritis susceptibility 6, focal segmental glomerulosclerosis 4, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 8, herpes simplex encephalitis, susceptibility to, 2, attention deficit-hyperactivity disorder, susceptibility to, 7, epilepsy, idiopathic generalized, susceptibility to, 10, pelvic organ prolapse, susceptibility to, 2, systemic lupus erythematosus, susceptibility to, 14, leprosy, susceptibility to, 5, thyrotoxic periodic paralysis, susceptibility to, 2, hearing loss, cisplatin-induced, susceptibility to, susceptibility to mononeuropathy of the median nerve, mild, fatty liver disease, nonalcoholic, susceptibility to, 2, leprosy, susceptibility to, 6, autoimmune disease, susceptibility to, 6, Parkinson disease 5, autosomal dominant, susceptibility to, aspergillosis, susceptibility to, sick sinus syndrome 3, susceptibility to, Parkinson disease 18, autosomal dominant, susceptibility to, epilepsy, juvenile myoclonic, susceptibility to, 9, dengue virus, susceptibility to, coronary heart disease, susceptibility to, 6, podoconiosis, susceptibility to, peripartum cardiomyopathy, susceptibility to, influenza, severe, susceptibility to, thyrotoxic periodic paralysis, susceptibility to, 3, human herpesvirus 8, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 12, herpes simplex encephalitis, susceptibility to, 3, herpes simplex encephalitis, susceptibility to, 4, pulmonary hypertension, neonatal, susceptibility to, craniosynostosis 5, susceptibility to, melioidosis, susceptibility to, chronic mountain sickness, susceptibility to, herpes simplex encephalitis, susceptibility to, 7, epilepsy, idiopathic generalized, susceptibility to, 14, hereditary neoplastic syndrome, autosomal recessive Mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency, autosomal recessive Mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency, susceptibility to localized juvenile periodontitis, inherited susceptibility to mycobacterial diseases, neural tube defects, susceptibility to, multiple system atrophy 1, susceptibility to, nephrolithiasis susceptibility caused by SLC26A1, myoclonic epilepsy, juvenile, susceptibility to, 1, epilepsy, childhood absence, susceptibility to, 1, autism, susceptiblity to, susceptibility to visceral leishmaniasis, 1, malaria, susceptibility to, spondyloarthropathy, susceptibility to, herpes simplex encephalitis, susceptibility to, 1, epilepsy, idiopathic generalized, susceptibility to, 18, epilepsy, idiopathic generalized, susceptibility to, 15, hepatitis, fulminant viral, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 16, autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial jak1 deficiency, aortic aneurysm, familial thoracic 11, susceptibility to, craniosynostosis 7, amyotrophic lateral sclerosis, susceptibility to, 24, amyotrophic lateral sclerosis, susceptibility to, 25, epilepsy, juvenile myoclonic, susceptibility to, 10, susceptibility to angioedema induced by ACE inhibitors, epidermodysplasia verruciformis, susceptibility to, exfoliation syndrome, susceptibility to, basal cell carcinoma, susceptibility to, graft-versus-host disease, susceptibility to, narcolepsy, susceptibility to, pulmonary disease, chronic obstructive, susceptibility to, restless legs syndrome, susceptibility to, psoriasis, susceptibility to, age related macular degeneration, susceptibility to, allergic rhinitis, susceptibility to, dermatitis, atopic, susceptibility to, Hirschsprung disease, susceptibility to, diabetes mellitus, ketosis-prone, schizophrenia, susceptibility to, radioulnar synostosis, nonsyndromic, susceptibility to, lumbar disk herniation, susceptibility to, lumbar disk degeneration, susceptibility to, psoriatic arthritis, susceptibility to, migraine with or without aura, susceptibility to, Alzheimer disease, susceptibility to, mitochondrial, Asperger syndrome, susceptibility to, tobacco addiction, susceptibility to, lipodystrophy, partial, acquired, susceptibility to, Graves disease, susceptibility to, 1, epilepsy, idiopathic generalized, susceptibility to, 17, breast-ovarian cancer, familial, susceptibility to, blepharospasm, benign essential, susceptibility to, hemorrhage, intracerebral, susceptibility to, IgA nephropathy, susceptibility to, hemolytic uremic syndrome, atypical, susceptibility to, 7, vitiligo-associated multiple autoimmune disease susceptibility 6, delayed sleep phase syndrome, susceptibility to, encephalitis, acute, infection-induced, susceptibility to, malignant hyperthermia, susceptibility to, multicentric Castleman disease, susceptibility to, pelvic organ prolapse, susceptibility to, 1, amyotrophic lateral sclerosis, susceptibility to, 13, Graves disease, susceptibility to, X-linked 2, autoimmune thyroid disease, susceptibility to, 5, atrioventricular septal defect, susceptibility to, 1, epilepsy, juvenile myoclonic, susceptibility to, 6, autoimmune disease, susceptibility to, 5, epilepsy, idiopathic generalized, susceptibility to, 6, seasonal affective disorder, susceptibility to, ventricular fibrillation during myocardial infarction, susceptibility to, UV-induced skin damage, susceptibility to, antisocial behavior, susceptibility to, aplastic anemia, susceptibility to, cardiomyopathy, familial hypertrophic, 4, susceptibility to, cirrhosis, noncryptogenic, susceptibility to, coronary artery disease, severe, susceptibility to, dengue fever, susceptibility to, dengue hemorrhagic fever, susceptibility to, dengue shock syndrome, susceptibility to, dyslexia, susceptibility to, 4, dyslexia, susceptibility to, 7, efavirenz central nervous system toxicity, susceptibility to, obesity, susceptibility to, Schistosoma mansoni infection, susceptibility/resistance to, Parkinson disease 24, autosomal dominant, susceptibility to, iron overload, susceptibility to, hydrocephalus, congenital, 5, susceptibility to, hearing loss, noise-induced, susceptibility to, hyperemesis gravidarum, susceptibility to, Parkinson disease 26, autosomal dominant, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 19, polycystic kidney disease 9, susceptibility to, rhabdomyolysis, susceptibility to, scoliosis, isolated, susceptibility to, dystonia 38, susceptibility to, gallbladder disease 4, epilepsy, juvenile absence, susceptibility to, GBA1-related Parkinson disease, susceptibility, SH2B3-related immune system disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

14 retrieved; paginated sample, class counts are floors:

7 uncertain significance, 2 likely pathogenic, 2 risk factor, 1 benign, 1 conflicting classifications of pathogenicity, 1 likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
1684472	NM_001060.6(TBXA2R):c.548G>A (p.Cys183Tyr)	TBXA2R	Likely pathogenic	no assertion criteria provided
3376276	NM_001060.6(TBXA2R):c.416C>A (p.Ser139Ter)	TBXA2R	Likely pathogenic	criteria provided, single submitter
29905	NM_001060.6(TBXA2R):c.910G>A (p.Asp304Asn)	TBXA2R	risk factor	no assertion criteria provided
39590	NM_001060.6(TBXA2R):c.722T>G (p.Val241Gly)	TBXA2R	risk factor	no assertion criteria provided
1703799	NM_001060.6(TBXA2R):c.840G>A (p.Gly280=)	TBXA2R	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1703800	NM_001060.6(TBXA2R):c.786+5G>A	TBXA2R	Uncertain significance	criteria provided, single submitter
1703801	NM_001060.6(TBXA2R):c.388C>T (p.Arg130Cys)	TBXA2R	Uncertain significance	criteria provided, multiple submitters, no conflicts
1703802	NM_001060.6(TBXA2R):c.620C>T (p.Ser207Leu)	TBXA2R	Uncertain significance	criteria provided, multiple submitters, no conflicts
2050485	NM_001060.6(TBXA2R):c.198C>G (p.Phe66Leu)	TBXA2R	Uncertain significance	criteria provided, single submitter
3044020	NM_001060.6(TBXA2R):c.*846G>C	TBXA2R	Uncertain significance	criteria provided, single submitter
3583636	NM_001060.6(TBXA2R):c.944T>G (p.Val315Gly)	TBXA2R	Uncertain significance	criteria provided, single submitter
3666648	NM_001060.6(TBXA2R):c.46A>G (p.Asn16Asp)	TBXA2R	Uncertain significance	criteria provided, multiple submitters, no conflicts
12712	NM_001060.6(TBXA2R):c.179G>T (p.Arg60Leu)	TBXA2R	Benign	criteria provided, single submitter
2070577	NM_001060.6(TBXA2R):c.196T>C (p.Phe66Leu)	TBXA2R	Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 4 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
TBXA2R	Moderate	Autosomal dominant	bleeding diathesis due to thromboxane synthesis deficiency	4

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TBXA2R	Orphanet:220443	Bleeding diathesis due to thromboxane synthesis deficiency

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TBXA2R	HGNC:11608	ENSG00000006638	P21731	Thromboxane A2 receptor	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TBXA2R	Thromboxane A2 receptor	Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
GPCR	1	23.9×	0.042

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TBXA2R	GPCR	yes		GPCR_Rhodpsn, Thbox_rcpt, Prostanoid_rcpt

Expression context

Cohort genes with no expression data: 0.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
olfactory bulb	1
tendon of biceps brachii	1
type B pancreatic cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TBXA2R	241	ubiquitous	yes	tendon of biceps brachii, type B pancreatic cell, olfactory bulb

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TBXA2R	1,074

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TBXA2R	P21731	6

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signal amplification	1	3806.7×	0.003	TBXA2R
Eicosanoid ligand-binding receptors	1	2284.0×	0.003	TBXA2R
Prostanoid ligand receptors	1	1268.9×	0.003	TBXA2R
Thromboxane signalling through TP receptor	1	475.8×	0.007	TBXA2R
G alpha (12/13) signalling events	1	137.6×	0.019	TBXA2R
Platelet activation, signaling and aggregation	1	105.7×	0.020	TBXA2R
Class A/1 (Rhodopsin-like receptors)	1	74.2×	0.025	TBXA2R
GPCR ligand binding	1	64.2×	0.025	TBXA2R
G alpha (q) signalling events	1	57.4×	0.025	TBXA2R
GPCR downstream signalling	1	43.4×	0.029	TBXA2R
Signaling by GPCR	1	40.1×	0.029	TBXA2R
Hemostasis	1	36.0×	0.030	TBXA2R
Signal Transduction	1	10.2×	0.098	TBXA2R

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of blood coagulation	1	1123.5×	0.004	TBXA2R
positive regulation of blood pressure	1	1053.2×	0.004	TBXA2R
negative regulation of cell migration involved in sprouting angiogenesis	1	991.3×	0.004	TBXA2R
positive regulation of smooth muscle contraction	1	936.2×	0.004	TBXA2R
smooth muscle contraction	1	802.5×	0.004	TBXA2R
positive regulation of vasoconstriction	1	601.9×	0.004	TBXA2R
response to testosterone	1	468.1×	0.005	TBXA2R
response to nutrient	1	295.6×	0.007	TBXA2R
response to ethanol	1	146.5×	0.012	TBXA2R
positive regulation of cytosolic calcium ion concentration	1	117.0×	0.012	TBXA2R
positive regulation of angiogenesis	1	115.4×	0.012	TBXA2R
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1	113.1×	0.012	TBXA2R
cellular response to lipopolysaccharide	1	98.0×	0.013	TBXA2R
response to xenobiotic stimulus	1	69.1×	0.017	TBXA2R
inflammatory response	1	37.7×	0.028	TBXA2R
G protein-coupled receptor signaling pathway	1	36.2×	0.028	TBXA2R

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TBXA2R	CANDESARTAN CILEXETIL

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TBXA2R	210	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CANDESARTAN CILEXETIL	4	TBXA2R
TELMISARTAN	4	TBXA2R
BEXAROTENE	4	TBXA2R
CLOTRIMAZOLE	4	TBXA2R
CHOLECALCIFEROL	4	TBXA2R
SIMVASTATIN	4	TBXA2R
METHYSERGIDE	4	TBXA2R
OXAPROZIN	4	TBXA2R
ENZALUTAMIDE	4	TBXA2R
CHLORMADINONE ACETATE	4	TBXA2R
RIMONABANT	4	TBXA2R
ARIPIPRAZOLE	4	TBXA2R
EZETIMIBE	4	TBXA2R
TORSEMIDE	4	TBXA2R
PONATINIB	4	TBXA2R
DESLORATADINE	4	TBXA2R
ESTRADIOL ACETATE	4	TBXA2R
TIOCONAZOLE	4	TBXA2R
BECLOMETHASONE DIPROPIONATE	4	TBXA2R
DYDROGESTERONE	4	TBXA2R
PHENYL AMINOSALICYLATE	4	TBXA2R
NORETHINDRONE ACETATE	4	TBXA2R
SERTACONAZOLE	4	TBXA2R
BROMODIPHENHYDRAMINE	4	TBXA2R
PYRVINIUM	4	TBXA2R
INDOCYANINE GREEN ACID FORM	4	TBXA2R
METHIXENE	4	TBXA2R
RABEPRAZOLE	4	TBXA2R
OXYBUTYNIN	4	TBXA2R
LURASIDONE	4	TBXA2R

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TBXA2R	307	Binding:199, Functional:107, ADMET:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TBXA2R	307

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
CANDESARTAN CILEXETIL	4	TBXA2R
TELMISARTAN	4	TBXA2R
BEXAROTENE	4	TBXA2R
CLOTRIMAZOLE	4	TBXA2R
CHOLECALCIFEROL	4	TBXA2R
SIMVASTATIN	4	TBXA2R
METHYSERGIDE	4	TBXA2R
OXAPROZIN	4	TBXA2R
ENZALUTAMIDE	4	TBXA2R
CHLORMADINONE ACETATE	4	TBXA2R
RIMONABANT	4	TBXA2R
ARIPIPRAZOLE	4	TBXA2R
EZETIMIBE	4	TBXA2R
TORSEMIDE	4	TBXA2R
PONATINIB	4	TBXA2R
DESLORATADINE	4	TBXA2R
ESTRADIOL ACETATE	4	TBXA2R
TIOCONAZOLE	4	TBXA2R
BECLOMETHASONE DIPROPIONATE	4	TBXA2R
DYDROGESTERONE	4	TBXA2R
PHENYL AMINOSALICYLATE	4	TBXA2R
NORETHINDRONE ACETATE	4	TBXA2R
SERTACONAZOLE	4	TBXA2R
BROMODIPHENHYDRAMINE	4	TBXA2R
PYRVINIUM	4	TBXA2R
INDOCYANINE GREEN ACID FORM	4	TBXA2R
METHIXENE	4	TBXA2R
RABEPRAZOLE	4	TBXA2R
OXYBUTYNIN	4	TBXA2R
LURASIDONE	4	TBXA2R

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	TBXA2R
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.